Should I buy or sell Sage Therapeutics stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 1 sell rating, 13 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks .

What is Sage Therapeutics' stock price target for 2024?

17 Wall Street research analysts have issued 12 month price objectives for Sage Therapeutics' shares. Their SAGE share price targets range from $14.00 to $294.00. On average, they anticipate the company's stock price to reach $39.28 in the next year. This suggests a possible upside of 201.3% from the stock's current price. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts .

How have SAGE shares performed in 2024?

Sage Therapeutics' stock was trading at $21.67 at the start of the year. Since then, SAGE stock has decreased by 39.8% and is now trading at $13.0350. View the best growth stocks for 2024 here .

When is Sage Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024. View our SAGE earnings forecast .

How can I listen to Sage Therapeutics' earnings call?

Sage Therapeutics will be holding an earnings conference call on Thursday, April 25th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link .

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.28) by $0.73. The biopharmaceutical company earned $77.97 million during the quarter, compared to analysts' expectations of $60.15 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 54.41% and a negative net margin of 626.32%. The company's quarterly revenue was up 2621.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.47) earnings per share.

What ETFs hold Sage Therapeutics' stock?

ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL) . Virtus LifeSci Biotech Products ETF (BBP) .

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA) , AbbVie (ABBV) , Micron Technology (MU) , Alibaba Group (BABA) , Advanced Micro Devices (AMD) , Gilead Sciences (GILD) , Netflix (NFLX) , Roku (ROKU) , QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY) .

Who are Sage Therapeutics' major shareholders?

Sage Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.11%) and Allspring Global Investments Holdings LLC (0.08%). Insiders that own company stock include Barry E Greene, Barry E Greene , Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas. View institutional ownership trends .

How do I buy shares of Sage Therapeutics?

Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Lowest-Rated StocksLowest-Rated

NASDAQ:SAGE

Sage Therapeutics (SAGE) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free SAGE Stock Alerts

$13.04

+0.46 (+3.66%)

(As of 04/18/2024 ET)

Compare

Today's Range: $12.20
▼
$13.50
50-Day Range: $12.57
▼
$25.75
52-Week Range: $10.92
▼
$59.99

Volume: 1.76 million shs
Average Volume: 1.01 million shs
Market Capitalization: $783.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $39.28

Get Sage Therapeutics alerts:

Sage Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.12 Rating Score
Upside/Downside: 201.3% Upside
$39.28 Price Target
Short Interest: Bearish
17.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.66
Upright™ Environmental Score
News Sentiment: -0.18
Based on 36 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($6.06) to ($4.32) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.14 out of 5 stars

Medical Sector

142nd out of 918 stocks

Pharmaceutical Preparations Industry

46th out of 402 stocks

4.1

Analyst's Opinion

Consensus Rating
Sage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.12, and is based on 3 buy ratings, 13 hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Sage Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
17.53% of the float of Sage Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Sage Therapeutics has a short interest ratio ("days to cover") of 9.1.
Change versus previous month
Short interest in Sage Therapeutics has recently increased by 2.38%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Sage Therapeutics does not currently pay a dividend.
Dividend Growth
Sage Therapeutics does not have a long track record of dividend growth.

4.3

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Sage Therapeutics has received a 65.22% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.
Environmental Sustainability
The Environmental Impact score for Sage Therapeutics is -1.66.

2.1

News and Social Media Coverage

News Sentiment
Sage Therapeutics has a news sentiment score of -0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 36 news articles for Sage Therapeutics this week, compared to 5 articles on an average week.
Search Interest
7 people have searched for SAGE on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
MarketBeat Follows
3 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sage Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Sage Therapeutics is held by insiders.
Percentage Held by Institutions
99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Sage Therapeutics are expected to grow in the coming year, from ($6.06) to ($4.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sage Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sage Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sage Therapeutics has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Sage Therapeutics Stock (NASDAQ:SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

SAGE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SAGE Stock News Headlines

April 18, 2024 | msn.com

B of A Securities Downgrades Sage Therapeutics (SAGE)

April 18, 2024 | markets.businessinsider.com

In-Depth Examination Of 9 Analyst Recommendations For Sage Therapeutics

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 18, 2024 | americanbankingnews.com

Sage Therapeutics (SAGE) Scheduled to Post Earnings on Thursday

April 17, 2024 | msn.com

Sage Therapeutics stock plunges 20 percent after Parkinson’s drug fails study

April 17, 2024 | benzinga.com

Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data

April 17, 2024 | msn.com

BofA downgrades Sage to underperform, cites failed Parkinson's study

April 17, 2024 | markets.businessinsider.com

Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | finance.yahoo.com

Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark

April 17, 2024 | investors.com

Sage Therapeutics Hammered After Parkinson's Drug Misses The Mark

April 17, 2024 | marketwatch.com

Sage Therapeutics Stops Further Development of Dalzanemdor in Parkinson's Disease

April 17, 2024 | marketwatch.com

Sage Therapeutics Shares Sink Premarket After Setback in Development of Dalzanemdor

April 17, 2024 | markets.businessinsider.com

Sage Therapeutics' Dalzanemdor Phase 2 Study Fails To Meet Primary Endpoint

April 17, 2024 | reuters.com

Sage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage study

April 17, 2024 | msn.com

Sage drops after mid-stage setback for Parkinson’s disease candidate

April 17, 2024 | finance.yahoo.com

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

April 13, 2024 | americanbankingnews.com

Leerink Partnrs Research Analysts Boost Earnings Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE)

April 12, 2024 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Hits New 1-Year Low at $15.88

April 12, 2024 | americanbankingnews.com

Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of "Hold" by Brokerages

April 11, 2024 | businesswire.com

Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024

April 3, 2024 | msn.com

Zelda: Tears of the Kingdom T-shirts are coming to Uniqlo in late April

March 28, 2024 | finance.yahoo.com

We're Keeping An Eye On Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Rate

March 26, 2024 | markets.businessinsider.com

Demystifying Sage Therapeutics: Insights From 5 Analyst Reviews

March 20, 2024 | msn.com

This company is treating postpartum depression in 2 weeks with a daily pill

March 11, 2024 | barrons.com

Sage Therapeutics Inc.

February 28, 2024 | markets.businessinsider.com

Peeling Back The Layers: Exploring Sage Therapeutics Through Analyst Insights

See More Headlines

Receive SAGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/18/2024
Next Earnings (Confirmed): 4/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SAGE
CUSIP: N/A
CIK: 1597553
Web: www.sagerx.com
Phone: (617) 299-8380
Fax: 617-299-8379
Employees: 487
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $39.28
High Stock Price Target: $294.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +201.3%
Consensus Rating: Hold
Rating Score (0-4): 2.12
Research Coverage: 17 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($9.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-541,490,000.00
Net Margins: -626.32%
Pretax Margin: -626.33%
Return on Equity: -54.41%
Return on Assets: -49.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.51
Quick Ratio: 10.51

Sales & Book Value

Annual Sales: $86.46 million
Price / Sales: 9.06
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $13.32 per share
Price / Book: 0.98

Miscellaneous

Outstanding Shares: 60,110,000
Free Float: 56,801,000
Market Cap: $783.53 million
Optionable: Optionable
Beta: 0.86

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Barry E. Greene (Age 61)
President, CEO & Director
Comp: $1.29M
Ms. Kimi E. Iguchi CPA (Age 62)
CFO & Treasurer
Comp: $665.37k
Ms. Anne Marie Cook Esq. (Age 62)
Senior VP, General Counsel & Secretary
Comp: $711.6k
Mr. Christopher Benecchi (Age 52)
Chief Business Officer
Comp: $703.76k
Dr. Laura Gault M.D.
Ph.D., Chief Medical Officer
Mr. Matt Lasmanis
Chief Technology & Innovation Officer
Mr. Mike Quirk
Chief Scientific Officer
Ashley Kaplowitz
Director of Investor Relations
Ms. Erin E. Lanciani (Age 55)
Chief People & Experience Officer
Dr. Amy Schacterle Ph.D.
Senior Vice President of R&D Strategy and Business Management

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SAGE Stock Analysis - Frequently Asked Questions

Should I buy or sell Sage Therapeutics stock right now?: 17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last year. There are currently 1 sell rating, 13 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares.
View SAGE analyst ratings or view top-rated stocks.
What is Sage Therapeutics' stock price target for 2024?: 17 Wall Street research analysts have issued 12 month price objectives for Sage Therapeutics' shares. Their SAGE share price targets range from $14.00 to $294.00. On average, they anticipate the company's stock price to reach $39.28 in the next year. This suggests a possible upside of 201.3% from the stock's current price.
View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts.
How have SAGE shares performed in 2024?: Sage Therapeutics' stock was trading at $21.67 at the start of the year. Since then, SAGE stock has decreased by 39.8% and is now trading at $13.0350.
View the best growth stocks for 2024 here.
When is Sage Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our SAGE earnings forecast.
How can I listen to Sage Therapeutics' earnings call?: Sage Therapeutics will be holding an earnings conference call on Thursday, April 25th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Sage Therapeutics' earnings last quarter?: Sage Therapeutics, Inc. (NASDAQ:SAGE) released its earnings results on Wednesday, February, 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.28) by $0.73. The biopharmaceutical company earned $77.97 million during the quarter, compared to analysts' expectations of $60.15 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 54.41% and a negative net margin of 626.32%. The company's quarterly revenue was up 2621.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.47) earnings per share.

What ETFs hold Sage Therapeutics' stock?: ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).Virtus LifeSci Biotech Products ETF (BBP).
What other stocks do shareholders of Sage Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY).
Who are Sage Therapeutics' major shareholders?: Sage Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.11%) and Allspring Global Investments Holdings LLC (0.08%). Insiders that own company stock include Barry E Greene, Barry E Greene, Elizabeth Barrett, George Golumbeski, James M Frates and Jeffrey M Jonas.
View institutional ownership trends.
How do I buy shares of Sage Therapeutics?: Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SAGE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Sage Therapeutics (SAGE) Stock Price, News & Analysis

Sage Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Sage Therapeutics Stock (NASDAQ:SAGE)

SAGE Stock Price History

SAGE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SAGE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™